QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ani-pharma-to-highlight-results-from-new-day-clinical-trial-of-iluvien-019-mg-for-use-in-dme-patients-in-late-breaking-oral-presentation-during-retina-subspecialty-day-2025-at-aao-meeting

ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ: ANIP) today announced that results from the NEW DAY...

 truist-securities-maintains-hold-on-ani-pharmaceuticals-raises-price-target-to-90

Truist Securities analyst Gregory Fraser maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and raises the price target...

 jp-morgan-maintains-overweight-on-ani-pharmaceuticals-raises-price-target-to-115

JP Morgan analyst Ekaterina Knyazkova maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Overweight and raises the price tar...

 hc-wainwright--co-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-121

HC Wainwright & Co. analyst Brandon Folkes maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price t...

 guggenheim-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-114

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $86 t...

 truist-securities-maintains-hold-on-ani-pharmaceuticals-raises-price-target-to-77

Truist Securities analyst Gregory Fraser maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and raises the price target...

 hc-wainwright--co-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-93

HC Wainwright & Co. analyst Brandon Folkes maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price t...

 ani-pharmaceuticals-raises-fy2025-adj-eps-guidance-from-627-662-to-698-735-vs-652-est-raises-fy2025-sales-guidance-from-768m-793m-to-818m-843m-vs-788076m-est

Full Year 2025 Guidance:Full Year 2025GuidancePrevious Full Year 2025Guidance2024 ActualGrowth Net Revenue (Total Company)$818 ...

Core News & Articles

CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a po...

 ani-pharmas-iluvien-cuts-injections-for-diabetic-eye-disease-post-hoc-study-shows-fewer-shots-needed-than-aflibercept

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN...

 hc-wainwright--co-initiates-coverage-on-ani-pharmaceuticals-with-buy-rating-announces-price-target-of-84

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy rating and...

 ani-pharma-launches-phase-4-trial-to-test-cortrophin-gel-dosing-for-gout-flares-at-massachusetts-general-hospital

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced the initiation of a Phase 4 clinical trial at Mas...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION